← Home / Sarepta Therapeutics, Inc. (SRPT)
Stock Analysis
Sarepta Therapeutics, Inc. (SRPT)
SRPT
SRPT · Market data
14.86 -4.50%
Track SRPT in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when SRPT price is:
52W Range Position
0%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 16:45 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Improving / Strong
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
16.94
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
27
●
Management / Board
MEDIUM
SRPT board and management update
On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc.
8-K Filing • SEC EDGAR
JUN
4
●
Management / Board
MEDIUM
SRPT board and management update
On June 4, 2026, Sarepta Therapeutics, Inc.
8-K Filing • SEC EDGAR
MAY
6
●
Financial Results
HIGH
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
– Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues – Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026, respectively – siRNA pip...
8-K Filing • SEC EDGAR
What's Driving SRPT?
📈 Technical recovery is improving
Momentum is Neutral. Watch 16.94 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Downtrend Structure
Downtrend line not broken yet · score 0
Trigger
22.55
RSI(14)
31.8
Price Chart
SRPT — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Loss
Earnings not meaningful
Earnings are negative or not useful, so sales, book value and cash-flow metrics matter more.
Market Cap
$1.6B
Company size
EV
$1.9B
Debt-adjusted value
P/E
-3.8
Not meaningful
P/S
3.5
Low sales multiple
P/B
1.0
Low book multiple
EV/Sales
4.4
Balanced
EV/EBIT
-2.8
Not meaningful
P/FCF
13.7
Low multiple
FCF Yield
7.32%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Improving business, cash flow needs monitoring
Revenue and profitability remain supportive, while cash flow and balance sheet quality require monitoring.
↗
Revenue Growth
Improving
●
Profitability
Strong
≈
Cash Flow
Pressured
⚖
Balance Sheet
Manageable
💵 Revenue
730.80M
↗ Improving
📈 Net Income
330.96M
↗ Strong
🧮 EPS (Basic)
3.15
↗ Strong
Sarepta Therapeutics, Inc.
Related Opportunities